Earnings Call Summary | Coherus BioSciences(CHRS.US) Q4 2023 Earnings Conference
Earnings Call Summary | Coherus BioSciences(CHRS.US) Q4 2023 Earnings Conference
The following is a summary of the Coherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call Transcript:
以下是Coherus BioSciences, Inc.（CHRS）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Coherus BioSciences reported Q4 combined net product revenue of $91.4 million, a 23% increase over Q3, with full-year net product revenue for 2023 being $256.6 million, a 22% increase over 2022.
UDENYCA revenue grew in Q4 with net sales of $36.2 million, a quarterly increase of 10%.
Q4 sales of CIMERLI generated $2.2 million, while the full-year 2023 sales were $3.6 million.
LOQTORZI recorded sales of $600,000 in Q4, based on initial wholesaler stocking for commercial launch.
The net loss for Q4 2023 was $79.7 million or $0.71 per share, compared to a net loss of $58.9 million or $0.76 per share for the same period in 2022.
Coherus ended the year with cash and cash equivalents of $117.7 million, compared to $192 million at the end of 2022.
Cost of goods sold (COGS) increased to $159 million in 2023, up from $70.1 million in 2022.
R&D expenses declined to $109.4 million. SG&A expenses decreased to $192 million for 2023, from $198.5 million in 2022.
Coherus BioSciences報告稱，第四季度合併淨產品收入爲9,140萬美元，比第三季度增長23％，2023年全年淨產品收入爲2.566億美元，比2022年增長22％。
UDENYCA收入在第四季度增長，淨銷售額爲3620萬美元，季度增長10％。
CIMERLI第四季度的銷售額創造了220萬美元，而2023年全年銷售額爲360萬美元。
根據批發商最初的商業上市庫存，LOQTORZI在第四季度的銷售額爲60萬美元。
2023年第四季度的淨虧損爲7,970萬美元，合每股虧損0.71美元，而2022年同期的淨虧損爲5,890萬美元，合每股虧損0.76美元。
Coherus年底的現金及現金等價物爲1.177億美元，而2022年底爲1.92億美元。
商品銷售成本（COGS）從2022年的7,010萬美元增加到2023年的1.59億美元。
研發費用降至1.094億美元。銷售和收購支出從2022年的1.985億美元降至2023年的1.92億美元。
Business Progress:
業務進展：
The company received timely FDA approval for UDENYCA and LOQTORZI for all lines of therapy in nasopharyngeal carcinoma.
Coherus published numerous positive phase 3 data sets for its drug, LOQTORZI, across various tumor types.
The company is currently enrolling patients for further investigation of casdozokitug in combination with toripalimab.
Coherus plans to strengthen its position in the market by offering three unique product options of UDENYCA to meet different needs.
For 2024, the company aims to achieve market share growth and profitability focusing on oncology products, particularly UDENYCA and LOQTORZI.
Coherus is also progressing with LOQTORZI, its treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC). Since its launch on January 2, 2023, 59 accounts have ordered LOQTORZI.
In 2024, the company plans to further reduce costs, decrease headcount, and divest non-core assets to achieve a sustainable growth path.
The company also plans to submit an IND for its anti-ILT4 antibody program, CHS-1000, in Q2 of 2024.
The company announced that UDENYCA sold 1 million units since its launch, representing a significant milestone.
該公司及時獲得了美國食品藥品管理局的批准，允許UDENYCA和LOQTORZI用於鼻咽癌的所有療法。
Coherus發佈了許多不同腫瘤類型的藥物LOQTORZI的3期陽性數據集。
該公司目前正在招收患者進一步研究casdozokitug與託瑞帕利單抗聯合用藥的情況。
Coherus計劃通過提供三種獨特的UDENYCA產品選項來鞏固其在市場上的地位，以滿足不同的需求。
2024年，該公司的目標是實現市場份額增長和盈利能力，重點是腫瘤產品，尤其是UDENYCA和LOQTORZI。
Coherus在治療複發性或轉移性鼻咽癌（NPC）的LOQTORZI方面也取得了進展。自 2023 年 1 月 2 日推出以來，已有 59 個賬戶訂購了 LOQTORZI。
2024年，該公司計劃進一步降低成本，減少員工人數，剝離非核心資產，以實現可持續增長之路。
該公司還計劃在2024年第二季度提交其抗ILT4抗體計劃 CHS-1000 的臨床試驗報告。
該公司宣佈，UDENYCA自推出以來已售出100萬臺，這是一個重要的里程碑。
More details: Coherus BioSciences IR
更多詳情： Coherus 生物科學紅外線
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。